AIDS research and therapy · 2026
Rapid identification of antigen-specific monoclonal antibodies from HIV-1 elite controllers using the Beacon platform.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Xiangyu, Zheng Xinyuan, Liang Rishen, Huang Lina, Shi Yu, Zhang Zhi, Yin Chengrui, Ding Chengchao, Wu Jiabing, Wu Jianjun, Gao Yong
Аннотация
Elite controllers (ECs) are rare human immunodeficiency virus (HIV)-infected individuals who manage viral replication without antiretroviral therapy. While their cellular immunity is well characterized, humoral responses remain limited, which provides an uncommon window into antibody responses to HIV-1. Using single-cell functional screening, this study aimed to isolate and characterize HIV-1 envelope (Env)-specific monoclonal antibodies (mAbs) from ECs. The Beacon platform was used for enrichment, activation, and screening of cluster of differentiation 27+ (CD27+) memory B cells. Among ~ 12,000 single B cells, 40 Env-specific IgG-secreting cells were identified. Although 18 mAbs were recovered, six showed high-affinity binding to multiple Env trimers (average EC50 < 100 ng/mL). Notably, one mAb (#2) demonstrated broad reactivity, neutralizing 15 of the 17 pseudoviruses, albeit with limited potency (geometric mean IC50 of 46.53 μg/mL). Sequence analysis revealed predominant usage of IGHV1-69 and varied somatic hypermutation levels. However, the high binding affinity could not consistently predict neutralization potency. This study demonstrated the utility of integrated single-cell screening for rapid discovery of antibodies from rare donors. This study also highlights the need for functional assessment in HIV-1 antibody development and identification of mAb candidates for potential therapeutic applications.